Amla (Phyllanthus emblica) y salud cardiometabólica: revisión narrativa con enfoque ecuatoriano
DOI:
https://doi.org/10.70577/asce.v5i4.1153Palabras clave:
amla; Phyllanthus emblica; síndrome metabólico; dislipidemias; hipertensión; EcuadorResumen
El amla (Phyllanthus emblica L.) se promociona cada vez más como un aliado natural de la salud cardiometabólica, en un país donde las enfermedades cardiovasculares y la diabetes encabezan las causas de muerte. Esta investigación reúne la evidencia sobre su repercusión a nivel glucémico, lipídico, presión arterial e inflamación y la examina desde el enfoque ecuatoriano. Se identificó varios estudios como ensayos clínicos, meta-análisis e investigaciones experimentales también para aportar el enfoque nacional se revisó datos epidemiológicos y normativa de sanidad con hincapié en publicación de los últimos 5 años. Uno de los meta-análisis más extensos (9 ensayos, 535 participantes) indicó disminución de LDL-C (−15,1 mg/dL), triglicéridos (−22,4 mg/dL) y proteína C reactiva ultrasensible (−1,7 mg/L), sin repercusión en HDL-C, ni en índices de presión arterial y con heterogeneidad alta; otro, centrado en extractos acuosos, valoró la veracidad de la evidencia como baja. El análisis de glicemia y peso corporal son pocos, de corta duración y, a veces, enlazados a los productores o en base a soluciones integradas sin grupo placebo. No se encontraron eventos adversos de gravedad, pero la interacción con antiagregantes es un área aún poco estudiada además no se identificó estudios en población ecuatoriana. La prevalencia de enfermedades crónicas no transmisibles, las deficiencias para el control de estas, la influencia de la altitud de la región serrana y la recomendación de uso de suplementos de origen herbario sin control en medios de comunicación digital sugiere precaución ante este compuesto. Amla es una opción coherente pero no una recomendación segura, para esto hace falta estudios regionales, personal sanitario capacitado para recomendar y concentraciones de AMLA bajo estricto control de calidad y dosificación.
Descargas
Citas
Acampado, L. R. T., Chiu, H. H. C., Larrazabal, R. B., Jr., Arcellana, A. E. S., y Añonuevo-Cruz, M. C. S. (2023). The efficacy and safety of Emblica officinalis aqueous fruit extract among adult patients with dyslipidemia: A systematic review and meta-analysis. Acta Medica Philippina, 57(5), 90–95. https://doi.org/10.47895/amp.vi0.5047
Agencia Nacional de Regulación, Control y Vigilancia Sanitaria. (2016). Resolución ARCSA-DE-023-2016-YMIH: Normativa sanitaria para la obtención del registro sanitario. https://faolex.fao.org/docs/pdf/ecu167164.pdf
Agencia Nacional de Regulación, Control y Vigilancia Sanitaria. (2026, 1 de octubre). Resolución ARCSA-DE-2026-021-DASP: Reforma parcial a la Normativa Técnica Sanitaria para la obtención de la notificación sanitaria y el control de suplementos alimenticios. Registro Oficial, Tercer Suplemento n.º 381.
Akhtar, M. S., Ramzan, A., Ali, A., y Ahmad, M. (2011). Effect of amla fruit (Emblica officinalis Gaertn.) on blood glucose and lipid profile of normal subjects and type 2 diabetic patients. International Journal of Food Sciences and Nutrition, 62(6), 609–616.
Anila, L., y Vijayalakshmi, N. R. (2002). Flavonoids from Emblica officinalis and Mangifera indica—Effectiveness for dyslipidemia. Journal of Ethnopharmacology, 79(1), 81–87. https://doi.org/10.1016/S0378-8741(01)00361-0
Antony, B., Merina, B., y Sheeba, V. (2008). Amlamax in the management of dyslipidemia in humans. Indian Journal of Pharmaceutical Sciences, 70(4), 504–507.
Arteaga, J. M., Latorre-Santos, C., Ibáñez-Pinilla, M., Ballesteros-Cabrera, M. P., Barón, L. Y., Velosa, S. A., Trillos, C. E., Duque, J. J., Holguín, A., y Eslava-Schmalbach, J. H. (2024). Prevalence of type 2 diabetes, overweight, obesity, and metabolic syndrome in adults in Bogotá, Colombia, 2022–2023: A cross-sectional population survey. Annals of Global Health, 90(1), 67. https://doi.org/10.5334/aogh.4539
Baethge, C., Goldbeck-Wood, S., y Mertens, S. (2019). SANRA—A scale for the quality assessment of narrative review articles. Research Integrity and Peer Review, 4, 5. https://doi.org/10.1186/s41073-019-0064-8
Baldeón, M. E., Felix, C., Fornasini, M., Zertuche, F., Largo, C., Paucar, M. J., Ponce, L., Rangarajan, S., Yusuf, S., y López-Jaramillo, P. (2021). Prevalence of metabolic syndrome and diabetes mellitus type-2 and their association with intake of dairy and legume in Andean communities of Ecuador. PLoS ONE, 16(7), e0254812. https://doi.org/10.1371/journal.pone.0254812
Behrouzi, M., Borazjani, F., Jafarirad, S., Zakerkish, M., Casazza, K., y Ahmadi Angali, K. (2025). Effects of curcumin and amla co-supplementation on lipid profile, glycemic status, antioxidant indices, inflammatory factor, and liver enzymes in type 2 diabetes patients: A double-blind, randomized controlled trial protocol. Jundishapur Journal of Natural Pharmaceutical Products, 20(1), e151530. https://doi.org/10.5812/jjnpp-151530
Bhatia, J., Tabassum, F., Sharma, A. K., Bharti, S., Golechha, M., Joshi, S., Akhtar, M. S., Srivastava, A. K., y Arya, D. S. (2011). Emblica officinalis exerts antihypertensive effect in a rat model of DOCA-salt-induced hypertension: Role of (p) eNOS, NO and oxidative stress. Cardiovascular Toxicology, 11(3), 272–279. https://doi.org/10.1007/s12012-011-9122-2
Bhattacharya, S., Gupta, N., Flekalová, A., Gordillo-Alarcón, S., Espinel-Jara, V., y Fernández-Cusimamani, E. (2024). Exploring folklore Ecuadorian medicinal plants and their bioactive components focusing on antidiabetic potential: An overview. Plants, 13(11), 1436. https://doi.org/10.3390/plants13111436
Brown, P. D. S., Ketter, N., Vis-Dunbar, M., y Sakakibara, B. M. (2023). Clinical effects of Emblica officinalis fruit consumption on cardiovascular disease risk factors: A systematic review and meta-analysis. BMC Complementary Medicine and Therapies, 23, 190. https://doi.org/10.1186/s12906-023-03997-8
Chamorro Valencia, D. X., Hurtado Lomas, C. R., y Romero González, P. E. (2024). Percepción y vulnerabilidad de los consumidores ante la publicidad de productos naturales medicinales en Ecuador. Dilemas Contemporáneos: Educación, Política y Valores, 12(EE1). https://doi.org/10.46377/dilemas.v12i.4470
Chen, X., Pan, D., Gui, L., Wu, R., Hao, Z., Yang, L., Wang, S., y Sun, G. (2026). Preventive effects of Phyllanthus emblica extract across tested doses in high-fat diet-induced obese rats. Advances in Traditional Medicine. Publicación anticipada en línea. https://doi.org/10.1007/s13596-026-00930-5
Fatima, N., Pingali, U., y Muralidhar, N. (2014). Study of pharmacodynamic interaction of Phyllanthus emblica extract with clopidogrel and ecosprin in patients with type II diabetes mellitus. Phytomedicine, 21(5), 579–585.
Fatima, N., Pingali, U., y Pilli, R. (2014). Evaluation of Phyllanthus emblica extract on cold pressor induced cardiovascular changes in healthy human subjects. Pharmacognosy Research, 6(1), 29–35. https://doi.org/10.4103/0974-8490.122914
Ghaffari, S., Navabzadeh, M., Ziaee, M., Ghobadi, A., Ghods, R., y Hashem-Dabaghian, F. (2020). A randomized, triple-blind, placebo-controlled, add-on clinical trial to evaluate the efficacy of Emblica officinalis in uncontrolled hypertension. Evidence-Based Complementary and Alternative Medicine, 2020, 8592869. https://doi.org/10.1155/2020/8592869
Gopa, B., Bhatt, J., y Hemavathi, K. G. (2012). A comparative clinical study of hypolipidemic efficacy of amla (Emblica officinalis) with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitor simvastatin. Indian Journal of Pharmacology, 44(2), 238–242. https://doi.org/10.4103/0253-7613.93857
Gul, M., Liu, Z.-W., Iahtisham-Ul-Haq, Rabail, R., Faheem, F., Walayat, N., Nawaz, A., Shabbir, M. A., Munekata, P. E. S., Lorenzo, J. M., y Aadil, R. M. (2022). Functional and nutraceutical significance of amla (Phyllanthus emblica L.): A review. Antioxidants, 11(5), 816. https://doi.org/10.3390/antiox11050816
Hajri, T., Caceres, L., y Angamarca-Armijos, V. (2021). The burden of hypertension in Ecuador: A systematic review and meta-analysis. Journal of Human Hypertension, 35, 389–397. https://doi.org/10.1038/s41371-020-00471-7
Hashem-Dabaghian, F., Ziaee, M., Ghaffari, S., Nabati, F., y Kianbakht, S. (2018). A systematic review on the cardiovascular pharmacology of Emblica officinalis Gaertn. Journal of Cardiovascular and Thoracic Research, 10(3), 118–128. https://doi.org/10.15171/jcvtr.2018.20
Hermans, M. P., Dierckxsens, Y., Janssens, I., Seidel, L., Albert, A., Ahn, S. A., Rousseau, M. F., y Khan, A. (2023). The antihyperlipidemic effect of a combined supplement of standardized dry extracts of amla (Emblica officinalis), walnut (Juglans regia), olive (Olea europaea) and red yeast rice (Monascus purpureus) powder: Reduction in circulatory LDL-C and remnant cholesterol levels in patients with hypercholesterolemia. Frontiers in Pharmacology, 14, 1280234. https://doi.org/10.3389/fphar.2023.1280234
Hermans, M. P., Ahn, S. A., Rousseau, M. F., Seidel, L., Albert, A., Janssens, I., Dierckxsens, Y., y Khan, A. (2024). Potential synergistic antihyperglycemic effects of co-supplemental amla and olive extracts in hyperlipidemic adults with prediabetes and type 2 diabetes: Results from a real-life clinical study. Frontiers in Nutrition, 11, 1462292. https://doi.org/10.3389/fnut.2024.1462292
Huang, C.-Z., Tung, Y.-T., Hsia, S.-M., Wu, C.-H., y Yen, G.-C. (2017). The hepatoprotective effect of Phyllanthus emblica L. fruit on high fat diet-induced non-alcoholic fatty liver disease (NAFLD) in SD rats. Food & Function, 8(2), 842–850.
Huang, S.-M., Lin, C.-H., Chang, W.-F., y Shih, C.-C. (2023). Antidiabetic and antihyperlipidemic activities of Phyllanthus emblica L. extract in vitro and the regulation of Akt phosphorylation, gluconeogenesis, and peroxisome proliferator-activated receptor α in streptozotocin-induced diabetic mice. Food & Nutrition Research, 67, 9854. https://doi.org/10.29219/fnr.v67.9854
Instituto Nacional de Estadística y Censos. (2024). Estadísticas vitales: Registro estadístico de defunciones generales de 2023. https://www.ecuadorencifras.gob.ec/documentos/web-inec/PoblacionyDemografia/DefuncionesGenerales/2023/PrincipalesresultadosEDG2023.pdf
International Diabetes Federation. (2025). IDF Diabetes Atlas (11.ª ed.). https://diabetesatlas.org
Jacob, A., Pandey, M., Kapoor, S., y Saroja, R. (1988). Effect of the Indian gooseberry (amla) on serum cholesterol levels in men aged 35–55 years. European Journal of Clinical Nutrition, 42(11), 939–944.
Kapoor, M. P., Suzuki, K., Derek, T., Ozeki, M., y Okubo, T. (2020). Clinical evaluation of Emblica officinalis Gatertn (amla) in healthy human subjects: Health benefits and safety results from a randomized, double-blind, crossover placebo-controlled study. Contemporary Clinical Trials Communications, 17, 100499. https://doi.org/10.1016/j.conctc.2019.100499
Karawita, U. G., Withana, S., Thasleem, S., Amarasena, J., Mahesh, B., Arnold, M., Ferdinando, R., y Gunathunga, W. (2023). Systematic review of the effect of Phyllanthus emblica in glycaemic control. Journal of the College of Community Physicians of Sri Lanka, 29(4), 311–327. https://doi.org/10.4038/jccpsl.v29i4.8476
Khanna, S., Das, A., Spieldenner, J., Rink, C., y Roy, S. (2015). Supplementation of a standardized extract from Phyllanthus emblica improves cardiovascular risk factors and platelet aggregation in overweight/class-1 obese adults. Journal of Medicinal Food, 18(4), 415–420.
Li, H.-Y., Li, C.-F., Liu, C.-H., Chen, S.-C., Liu, Y.-F., Lv, Q.-H., y Zhang, W. (2024). Extract of Phyllanthus emblica L. fruit stimulates basal glucose uptake and ameliorates palmitate-induced insulin resistance through AMPK activation in C2C12 myotubes. BMC Complementary Medicine and Therapies, 24(1), 296.
Lin, H.-Y., Lin, C.-H., Kuo, Y.-H., y Shih, C.-C. (2024). Antidiabetic and antihyperlipidemic activities and molecular mechanisms of Phyllanthus emblica L. extract in mice on a high-fat diet. Current Issues in Molecular Biology, 46(9), 10492–10529. https://doi.org/10.3390/cimb46090623
Luo, X., Zhang, B., Pan, Y., Gu, J., Tan, R., y Gong, P. (2022). Phyllanthus emblica aqueous extract retards hepatic steatosis and fibrosis in NAFLD mice in association with the reshaping of intestinal microecology. Frontiers in Pharmacology, 13, 893561. https://doi.org/10.3389/fphar.2022.893561
Majeed, M., Majeed, S., Mundkur, L., Nagabhushanam, K., Arumugam, S., Beede, K., y Ali, F. (2020). Standardized Emblica officinalis fruit extract inhibited the activities of α-amylase, α-glucosidase, and dipeptidyl peptidase-4 and displayed antioxidant potential. Journal of the Science of Food and Agriculture, 100(2), 509–516. https://doi.org/10.1002/jsfa.10020
Majeed, M., Mundkur, L., Paulose, S., y Nagabhushanam, K. (2022). Novel Emblica officinalis extract containing β-glucogallin vs. metformin: A randomized, open-label, comparative efficacy study in newly diagnosed type 2 diabetes mellitus patients with dyslipidemia. Food & Function, 13(18), 9523–9531. https://doi.org/10.1039/D2FO01862D
Majeed, M., Narayanan, N. K., Mundkur, L., Prakasan, P., y Nagabhushanam, K. (2023). Super fruit amla (Emblica officinalis, Gaertn) in diabetes management and ensuing complications: A concise review. Nutraceuticals, 3(3), 329–352. https://doi.org/10.3390/nutraceuticals3030026
Martinez, V., McAngus, K., Dickerson, B. L., Leonard, M., Chavez, E., Chun, J., Lewis, M., Xing, D., Gonzalez, D. E., Yoo, C., Ko, J., Rhodes, H., Lee, H., Sowinski, R. J., Rasmussen, C. J., y Kreider, R. B. (2025). Effects of 12 weeks of chromium, Phyllanthus emblica fruit extract, and shilajit supplementation on markers of cardiometabolic health, fitness, and weight loss in men and women with risk factors to metabolic syndrome initiating an exercise and diet intervention: A randomized double-blind, placebo-controlled trial. Nutrients, 17(12), 2042. https://doi.org/10.3390/nu17122042
Mathur, R., Sharma, A., Dixit, V. P., y Varma, M. (1996). Hypolipidaemic effect of fruit juice of Emblica officinalis in cholesterol-fed rabbits. Journal of Ethnopharmacology, 50(2), 61–68. https://doi.org/10.1016/0378-8741(95)01308-3
Ministerio de Salud Pública del Ecuador. (2020). Encuesta STEPS Ecuador 2018: Informe de resultados. https://www.salud.gob.ec/wp-content/uploads/2020/10/INFORME-STEPS.pdf
Mottillo, S., Filion, K. B., Genest, J., Joseph, L., Pilote, L., Poirier, P., Rinfret, S., Schiffrin, E. L., y Eisenberg, M. J. (2010). The metabolic syndrome and cardiovascular risk: A systematic review and meta-analysis. Journal of the American College of Cardiology, 56(14), 1113–1132. https://doi.org/10.1016/j.jacc.2010.05.034
Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., Coresh, J., Mathew, R. O., Baker-Smith, C. M., Carnethon, M. R., Despres, J.-P., Ho, J. E., Joseph, J. J., Kernan, W. N., Khera, A., Kosiborod, M. N., Lekavich, C. L., Lewis, E. F., Lo, K. B., . . . Elkind, M. S. V. (2023). Cardiovascular-kidney-metabolic health: A presidential advisory from the American Heart Association. Circulation, 148(20), 1606–1635. https://doi.org/10.1161/CIR.0000000000001184
Noubiap, J. J., Nansseu, J. R., Nyaga, U. F., Ndoadoumgue, A. L., Ngouo, A. T., Tounouga, D. N., Tianyi, F. L., Foka, A. J., Lontchi-Yimagou, E., Nkeck, J. R., y Bigna, J. J. (2025). Worldwide trends in metabolic syndrome from 2000 to 2023: A systematic review and modelling analysis. Nature Communications, 17(1), 573. https://doi.org/10.1038/s41467-025-67268-5
Ortiz, P., Vásquez, Y., Arévalo, E., Van der Stuyft, P., y Londoño Agudelo, E. (2022). Gaps in hypertension management in a middle-income community of Quito-Ecuador: A population-based study. International Journal of Environmental Research and Public Health, 19(10), 5832. https://doi.org/10.3390/ijerph19105832
Ortiz-Prado, E., Izquierdo-Condoy, J. S., Fernández-Naranjo, R., Vásconez-González, J., Cano, L., González, A. C., Morales-Lapo, E., Guerrero-Castillo, G. S., Duque, E., Dávila Rosero, M. G., Egas, D., y Viscor, G. (2023). Epidemiological characterization of ischemic heart disease at different altitudes: A nationwide population-based analysis from 2011 to 2021 in Ecuador. PLoS ONE, 18(12), e0295586. https://doi.org/10.1371/journal.pone.0295586
Parra-Gómez, L. A., Puerta Rojas, J. P., Vásquez, A. J., Escalante Remolina, M. A., Lora Mantilla, A. J., Villabona Flórez, S. J., y Camacho López, P. A. (2025). Prevalence of metabolic syndrome in Latin America: A systematic review and meta-analysis of observational studies. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 19(7), 103282. https://doi.org/10.1016/j.dsx.2025.103282
Pérez-Galarza, J., Baldeón, L., Franco, O. H., Muka, T., Drexhage, H. A., Voortman, T., y Freire, W. B. (2021). Prevalence of overweight and metabolic syndrome, and associated sociodemographic factors among adult Ecuadorian populations: The ENSANUT-ECU study. Journal of Endocrinological Investigation, 44(1), 63–74. https://doi.org/10.1007/s40618-020-01267-9
Prananda, A. T., Dalimunthe, A., Harahap, U., Simanjuntak, Y., Peronika, E., Karosekali, N. E., Hasibuan, P. A. Z., Syahputra, R. A., Situmorang, P. C., y Nurkolis, F. (2023). Phyllanthus emblica: A comprehensive review of its phytochemical composition and pharmacological properties. Frontiers in Pharmacology, 14, 1288618. https://doi.org/10.3389/fphar.2023.1288618
Puppala, M., Ponder, J., Suryanarayana, P., Reddy, G. B., Petrash, J. M., y LaBarbera, D. V. (2012). The isolation and characterization of β-glucogallin as a novel aldose reductase inhibitor from Emblica officinalis. PLoS ONE, 7(4), e31399. https://doi.org/10.1371/journal.pone.0031399
Rathore, R., Yadav, A., Khatkar, A., Suhag, D., Vrushabaiah, G. K., y Govindaraj, S. (2025). Effect of amla extract on body mass index, waist circumference, total body fat, visceral fat, skeletal muscle mass, body age, and related parameters: A randomized, open-label clinical study in obese participants. Complementary Medicine Research, 32(4), 326–340. https://doi.org/10.1159/000545247
Setayesh, L., Haghighat, N., Rasaei, N., Rezaei, M., Casazza, K., Nadery, M., Yamrali, I., Zamani, M., y Asbaghi, O. (2023). The impact of Emblica officinalis (amla) on lipid profile, glucose, and C-reactive protein: A systematic review and meta-analysis of randomized controlled trials. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 17(3), 102729. https://doi.org/10.1016/j.dsx.2023.102729
Shanmugarajan, D., Girish, C., Harivenkatesh, N., Chanaveerappa, B., y Prasanna Lakshmi, N. C. (2021). Antihypertensive and pleiotropic effects of Phyllanthus emblica extract as an add-on therapy in patients with essential hypertension—A randomized double-blind placebo-controlled trial. Phytotherapy Research, 35(6), 3275–3285. https://doi.org/10.1002/ptr.7043
Thilakchand, K. R., Mathai, R. T., Simon, P., Ravi, R. T., Baliga-Rao, M. P., y Baliga, M. S. (2013). Hepatoprotective properties of the Indian gooseberry (Emblica officinalis Gaertn): A review. Food & Function, 4(10), 1431–1441. https://doi.org/10.1039/c3fo60237k
Tiwana, G., Cock, I. E., y Cheesman, M. J. (2025). Phyllanthus emblica: Phytochemistry, antimicrobial potential with antibiotic enhancement, and toxicity insights. Microorganisms, 13(3), 611. https://doi.org/10.3390/microorganisms13030611
Upadya, H., Prabhu, S., Prasad, A., Subramanian, D., Gupta, S., y Goel, A. (2019). A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia. BMC Complementary and Alternative Medicine, 19(1), 27. https://doi.org/10.1186/s12906-019-2430-y
Usharani, P., Fatima, N., y Muralidhar, N. (2013). Effects of Phyllanthus emblica extract on endothelial dysfunction and biomarkers of oxidative stress in patients with type 2 diabetes mellitus: A randomized, double-blind, controlled study. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 6, 275–284. https://doi.org/10.2147/DMSO.S46341
Usharani, P., Merugu, P. L., y Nutalapati, C. (2019). Evaluation of the effects of a standardized aqueous extract of Phyllanthus emblica fruits on endothelial dysfunction, oxidative stress, systemic inflammation and lipid profile in subjects with metabolic syndrome: A randomised, double blind, placebo controlled clinical study. BMC Complementary and Alternative Medicine, 19, 97. https://doi.org/10.1186/s12906-019-2509-5
Variya, B. C., Bakrania, A. K., y Patel, S. S. (2016). Emblica officinalis (amla): A review for its phytochemistry, ethnomedicinal uses and medicinal potentials with respect to molecular mechanisms. Pharmacological Research, 111, 180–200.
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., Djousse, L., Elkind, M. S. V., Ferguson, J. F., Fornage, M., Khan, S. S., Kissela, B. M., Knutson, K. L., Kwan, T. W., Lackland, D. T., . . . Tsao, C. W. (2020). Heart disease and stroke statistics—2020 update: A report from the American Heart Association. Circulation, 141(9), e139–e596. https://doi.org/10.1161/CIR.0000000000000757
World Health Organization. (2023, 19 de septiembre). First WHO report details devastating impact of hypertension and ways to stop it. https://www.who.int/en/news/item/19-09-2023-first-who-report-details-devastating-impact-of-hypertension-and-ways-to-stop-it
Yadav, S. S., Singh, M. K., Singh, P. K., y Kumar, V. (2017). Traditional knowledge to clinical trials: A review on therapeutic actions of Emblica officinalis. Biomedicine & Pharmacotherapy, 93, 1292–1302.
Yan, X., Li, Q., Jing, L., Wu, S., Duan, W., Chen, Y., Chen, D., y Pan, X. (2022). Current advances on the phytochemical composition, pharmacologic effects, toxicology, and product development of Phyllanthi Fructus. Frontiers in Pharmacology, 13, 1017268. https://doi.org/10.3389/fphar.2022.1017268
Zila-Velasque, J. P., Grados-Espinoza, P., Challapa-Mamani, M. R., Sánchez-Alcántara, F., Cedillo-Balcázar, J., Aziz-Delgado, C. S., Hernandez-Bustamante, E. A., Tejada-Flores, J., Piano Suárez, A., Pacheco-Mendoza, J., y Benites-Zapata, V. A. (2024). Prevalence of metabolic syndrome and its components according to altitude levels: A systematic review and meta-analysis. Scientific Reports, 14(1), 27581. https://doi.org/10.1038/s41598-024-77928-z
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2026 Gyna Michelle Galarza Sánchez, Mgtr., Viviana Michelle Paucar Chalán, Mgtr., Ana Gabriela Espinosa García, Mgtr, Marco Antonio Mármol Santillán, Mgtr.

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Eres libre de:
- Compartir : copiar y redistribuir el material en cualquier medio o formato
- Adaptar : remezclar, transformar y desarrollar el material
- El licenciante no puede revocar estas libertades siempre y cuando usted cumpla con los términos de la licencia.
En los siguientes términos:
- Atribución : Debe otorgar el crédito correspondiente , proporcionar un enlace a la licencia e indicar si se realizaron cambios . Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o a su uso.
- No comercial : no puede utilizar el material con fines comerciales .
- CompartirIgual — Si remezcla, transforma o construye sobre el material, debe distribuir sus contribuciones bajo la misma licencia que el original.
- Sin restricciones adicionales : no puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otros hacer algo que la licencia permite.














